199 related articles for article (PubMed ID: 32526450)
1. Translational considerations in nanomedicine: The oncology perspective.
Gabizon AA; de Rosales RTM; La-Beck NM
Adv Drug Deliv Rev; 2020; 158():140-157. PubMed ID: 32526450
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.
Anchordoquy TJ; Barenholz Y; Boraschi D; Chorny M; Decuzzi P; Dobrovolskaia MA; Farhangrazi ZS; Farrell D; Gabizon A; Ghandehari H; Godin B; La-Beck NM; Ljubimova J; Moghimi SM; Pagliaro L; Park JH; Peer D; Ruoslahti E; Serkova NJ; Simberg D
ACS Nano; 2017 Jan; 11(1):12-18. PubMed ID: 28068099
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine: is it lost in translation?
Greish K; Mathur A; Bakhiet M; Taurin S
Ther Deliv; 2018 Mar; 9(4):269-285. PubMed ID: 29495928
[TBL] [Abstract][Full Text] [Related]
4. Optically modulated cancer therapeutic delivery: past, present and future.
Strong LE; West JL
Ther Deliv; 2015; 6(5):545-58. PubMed ID: 26001172
[TBL] [Abstract][Full Text] [Related]
5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
[TBL] [Abstract][Full Text] [Related]
7. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Shi J; Xiao Z; Kamaly N; Farokhzad OC
Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
Cadete A; Alonso MJ
Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle approaches to combating drug resistance.
Moon JH; Moxley JW; Zhang P; Cui H
Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
[TBL] [Abstract][Full Text] [Related]
10. Imaging-guided nanomedicine development.
Bernal A; Calcagno C; Mulder WJM; Pérez-Medina C
Curr Opin Chem Biol; 2021 Aug; 63():78-85. PubMed ID: 33735814
[TBL] [Abstract][Full Text] [Related]
11. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions.
Anchordoquy T; Artzi N; Balyasnikova IV; Barenholz Y; La-Beck NM; Brenner JS; Chan WCW; Decuzzi P; Exner AA; Gabizon A; Godin B; Lai SK; Lammers T; Mitchell MJ; Moghimi SM; Muzykantov VR; Peer D; Nguyen J; Popovtzer R; Ricco M; Serkova NJ; Singh R; Schroeder A; Schwendeman AA; Straehla JP; Teesalu T; Tilden S; Simberg D
ACS Nano; 2024 Jun; 18(22):13983-13999. PubMed ID: 38767983
[TBL] [Abstract][Full Text] [Related]
13. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
[TBL] [Abstract][Full Text] [Related]
14. Smart Drug-Delivery Systems for Cancer Nanotherapy.
Sanchez-Moreno P; Ortega-Vinuesa JL; Peula-Garcia JM; Marchal JA; Boulaiz H
Curr Drug Targets; 2018 Feb; 19(4):339-359. PubMed ID: 27231107
[TBL] [Abstract][Full Text] [Related]
15. A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity.
England CG; Ng CF; van Berkel V; Frieboes HB
Curr Drug Targets; 2015; 16(10):1057-87. PubMed ID: 25944016
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
17. Liposomes as a Promising Ultrasound-Triggered Drug Delivery System in Cancer Treatment.
Salkho NM; Turki RZ; Guessoum O; Martins AM; Vitor RF; Husseini GA
Curr Mol Med; 2017; 17(10):668-688. PubMed ID: 29663885
[TBL] [Abstract][Full Text] [Related]
18. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
